4559 On Other Exchanges
4559 is not on other exchanges.

zeria pharmaceutical co ltd (4559) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZERIA PHARMACEUTICAL CO LTD (4559)

Related News

No related news articles were found.

zeria pharmaceutical co ltd (4559) Related Businessweek News

No Related Businessweek News Found

zeria pharmaceutical co ltd (4559) Details

Zeria Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents. It also provides cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, and analytical equipment. The company’s primary products comprise gastrointestinal ethical products, including therapeutic agents for functional dyspepsia, ulcerative colitis, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; and proton pump inhibitors, as well as therapeutic agents for hypophosphatemia, calcium channel blocker, oral NSAID, anti-leukopenia after radiotherapy, sclerosing agents for varicose veins, topical NSAID, anti-inflammatory topical blood circulation enhancer, non-steroidal anti-inflammatory ophthalmic solution, and absorbable topical hemostat products. Its products also include OTC drugs and products, such as self-prevention, remedies for gastrointestinal diseases, western herbal medicine, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. The company was founded in 1955 and is headquartered in Tokyo, Japan.

1,799 Employees
Last Reported Date: 06/29/16
Founded in 1955

zeria pharmaceutical co ltd (4559) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeria pharmaceutical co ltd
Zeria Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2017

Zeria Pharmaceutical Co., Ltd. announced consolidated earnings results for the nine months ended December 31, 2016. For the period, the company reported net sales of JPY 49,043 million compared to JPY 47,054 million a year ago. Operating income was JPY 3,641 million compared to JPY 3,792 million a year ago. Ordinary income was JPY 3,502 million compared to JPY 3,766 million a year ago. Profit attributable to owners of parent was JPY 2,873 million or JPY 54.10 per basic share compared to JPY 3,335 million or JPY 62.79 per basic share a year ago. The company provided consolidated earnings guidance for the full year ending March 31, 2017. For the year, the company expects net sales of JPY 66,000 million, operating income of JPY 4,800 million, ordinary income of JPY 4,600 million and profit attributable to owners of parent of JPY 3,600 million or JPY 67.78 per basic share.

Zeria Pharmaceutical Co., Ltd. to Report Q3, 2017 Results on Feb 08, 2017

Zeria Pharmaceutical Co., Ltd. announced that they will report Q3, 2017 results on Feb 08, 2017

Zeria Pharmaceutical Launches Zentacort 3mg Capsules in Japan for Treatment in Crohn's Disease

Zeria Pharmaceutical Co., Ltd. launched Zentacort(R) 3mg capsules (generic name: Budesonide) in Japan on November 29, 2016. Zentacort(R) is sold as Entocort(TM) in more than 40 countries and recommended as first line therapy for treatment in Crohn's Disease (CD) in various international guidelines. Zentacort(R) has an indication for the treatment of mild to moderate active CD and is now listed on the NHI drug reimbursement price list in Japan. The Study Group on Unapproved and Off-label Drugs of High Medical Need, operating under the Japanese Ministry of Labour, Health and Welfare (MHLW), concluded that there was a substantial need to make Zentacort(R) available for use in treatment in Crohn's disease in Japan. Responding to a request from the MHLW, AstraZeneca started the development of Zentacort(R) in December 2010. Product name in Japan: Zentacort(R) 3mg capsules; Generic name: Budesonide; Formulation: Capsules Indication: Mild to moderate active Crohn's Disease; Dosage and administration: Usually for adults, 9mg is orally administered once a day in the morning. Package Zentacort(R) 3mg capsules: 100 capsules/bottle. Date of approval is 28 September 2016. Date of launch 29 November 2016. Drug price: Zentacort(R) 3mg Capsules 256.90 yen. Approval holder: Zeria Pharmaceutical Co., Ltd.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4559 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4559.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4559 Industry Range
Price/Earnings 30.7x
Price/Sales 1.5x
Price/Book 1.6x
Price/Cash Flow 30.7x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ZERIA PHARMACEUTICAL CO LTD, please visit www.zeria.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.